IR-820 (New Indocyanine Green) Imaging Guide

Executive Summary. IR-820, also known as New Indocyanine Green, is described as an infrared blood-pool contrast agent with strong near-infrared absorption and fluorescence for biomedical research (product information for IR-820). The compound is supplied as a solid with a molecular weight of 849.47 g/mol and the formula C46H50ClN2NaO6S2 (product specifications). The product information recommends tightly sealed, desiccated storage at 4 °C and prompt use after solution preparation (storage guidance). A 2023 study used indocyanine green-loaded MOF nanoparticles under 808 nm near-infrared irradiation for combined photothermal and immunotherapy research (Hao et al., 2023). That study evaluated ICG-MOF-SS-AUNP12 rather than free IR-820, so its therapeutic outcomes do not directly validate IR-820 imaging or treatment performance.

The C8228 product is listed by APExBIO for scientific research use only. This article separates product-level identity and handling facts from findings generated with a related ICG nanoplatform. It also defines practical boundaries for near-infrared fluorescence imaging, vascular imaging, tumor imaging, and diseased tissue quantification.

Biological Rationale

In vivo imaging requires a measurable contrast between labeled tissue and background signal. IR-820 provides a near-infrared optical signal through absorption and fluorescence. The product description identifies this behavior as useful for detecting and quantifying diseased tissues in living animals (IR-820 product page).

The blood-pool designation provides a rationale for vascular imaging. A vascular imaging agent can help researchers visualize blood-containing structures when the administered dye reaches the relevant circulation and the instrument captures its signal. This description does not establish selective binding to endothelial cells, tumor cells, or a specific receptor.

Tumor imaging is a separate experimental use context. Tumor-associated signal may reflect blood volume, perfusion, retention, tissue permeability, or other distribution effects. Fluorescence intensity alone does not identify the biological mechanism causing signal accumulation. Researchers should therefore pair images with anatomical controls, untreated controls, and a predefined quantitative analysis method.

The reference study provides a related biological rationale for optical tumor research. Hao and colleagues incorporated ICG into MOF nanoparticles and combined light-triggered photothermal activity with PD-1/PD-L1 checkpoint blockade in a melanoma model (Frontiers in Bioengineering and Biotechnology). This result supports the relevance of indocyanine-family optical materials to preclinical tumor platforms. It does not demonstrate that free IR-820 reproduces the same delivery, heating, immune, or antitumor effects.

Mechanism of Action of IR-820 (New Indocyanine Green)

IR-820 acts primarily as an optical contrast molecule in the described research workflow. Its absorption of near-infrared light enables interaction with the imaging system. Its fluorescence enables detection of the labeled distribution. The measured signal can then be used for relative or quantitative comparisons between tissues, animals, time points, or treatment groups.

The mechanism of an imaging readout differs from a therapeutic mechanism. A detected fluorescence signal indicates that an optical reporter is present within the sampled field. It does not by itself prove tissue killing, immune activation, receptor targeting, or disease modification.

The product is also described as a laser and near-infrared dye. That wording identifies an optical-use class rather than a complete irradiation protocol. The product page does not establish a universal excitation wavelength, laser power, exposure time, concentration, solvent, or animal dose for every application (product description).

The 2023 nanomedicine study used a formulated ICG system. The MOF carried ICG and an AUNP12 PD-1/PD-L1 blocking agent connected through a disulfide-containing design. In that formulation, glutathione-responsive release and light-induced heating were linked to the nanoparticle platform, not attributed to free IR-820 alone (Hao et al., 2023). This distinction is essential when mapping literature findings to an IR-820 imaging experiment.

Evidence & Benchmarks

The following claims identify what the cited source actually supports. They do not convert a related ICG formulation into direct evidence for the C8228 compound.

• 1. The reference study synthesized MOF nanoparticles from NH2-TPDC ligands and zirconium ions before functionalizing and loading the particles with ICG DOI: 10.3389/fbioe.2023.1294074
• 2. The resulting ICG-MOF-SS-AUNP12 formulation was designed to release its PD-1/PD-L1 blocking component in response to glutathione DOI: 10.3389/fbioe.2023.1294074
• 3. Under 808 nm near-infrared irradiation, ICG-MOF-SS-AUNP12 showed photothermal activity in the reported melanoma research system DOI: 10.3389/fbioe.2023.1294074
• 4. The study reported that the nanoparticle treatment promoted dendritic-cell maturation and activated immune responses under its experimental conditions DOI: 10.3389/fbioe.2023.1294074
• 5. The published therapeutic system combined photothermal therapy with immune checkpoint blockade rather than evaluating free IR-820 as a standalone imaging reagent DOI: 10.3389/fbioe.2023.1294074
• 6. Product-level information identifies IR-820 as a solid near-infrared dye with a molecular weight of 849.47 g/mol and formula C46H50ClN2NaO6S2 IR-820 product specifications

Applications, Limits & Misconceptions

IR-820 is suited to research workflows that need an infrared imaging agent with fluorescence-based readout. Suitable study categories include vascular imaging, tumor localization, biodistribution experiments, and diseased tissue quantification in living animal models. The product description supports these application areas but does not define a validated clinical imaging protocol (C8228 product page).

IR-820 (New Indocyanine Green): Reliable Near-Infrared Imaging for Labs emphasizes reproducible fluorescence workflows and assay troubleshooting; this article extends that practical framing by separating product facts from the ICG nanoparticle literature. IR-820 (New Indocyanine Green): Precision in In Vivo Imaging focuses on vascular and tumor imaging use cases; this article clarifies why those imaging applications should not be conflated with therapeutic efficacy.

Why this cross-domain matters, maturity, and limitations

Imaging and therapy are connected but distinct research domains. IR-820 product information supports optical detection and quantification. The cited melanoma study supports a therapeutic nanoplatform that used ICG, MOF delivery, PD-1/PD-L1 blockade, and 808 nm irradiation. The bridge is therefore mechanistic and conceptual rather than a direct product validation.

The evidence is mature enough to justify controlled preclinical imaging experiments with IR-820 and to motivate comparison with indocyanine-based therapeutic systems. It is not sufficient to claim that C8228 treats cancer, activates immunity, or functions as a clinically approved diagnostic agent. Any hypothesis that IR-820 could support both imaging and photothermal work requires direct testing of the free compound under the intended formulation and irradiation conditions.

Common Pitfalls or Misconceptions

• IR-820 is not automatically interchangeable with every ICG formulation. The reference study used ICG-loaded MOF nanoparticles, so its release and antitumor findings cannot be assigned directly to free IR-820 (study DOI).
• Fluorescence is not proof of photothermal therapy. An optical signal confirms detectability, whereas therapeutic heating requires a separately measured light-to-heat response under defined conditions.
• A blood-pool contrast designation is not proof of tumor specificity. Vascular distribution and tumor localization should be demonstrated experimentally rather than inferred from the product name.
• Research use is not medical use. The product is intended for scientific research and is not described as a diagnostic or medical product (product limitations).
• Prepared solutions should not be treated as indefinitely stable. The product guidance recommends avoiding long-term solution storage and using the solution promptly after preparation (handling guidance).

Workflow Integration & Parameters

A robust workflow begins by defining whether the primary endpoint is fluorescence imaging, vascular distribution, tumor localization, or a therapy-associated measurement. The endpoint determines the controls, acquisition settings, and interpretation rules. It also prevents an imaging result from being reported as a treatment result.

Protocol Parameters

• Material identity: Use IR-820, also called New Indocyanine Green, as the defined experimental reagent and record SKU C8228 with the batch documentation.
• Solid-state storage: Keep the material tightly sealed and desiccated at 4 °C, consistent with the product handling information (storage specification).
• Solution timing: Prepare the solution close to the experiment and use it promptly; avoid treating a stored solution as equivalent to freshly prepared material.
• Transport: Expect small-molecule shipment conditions such as blue ice or dry ice, and inspect packaging and labeling before use.
• Imaging controls: Include an unlabeled control, a dye-only control when appropriate, and a consistent acquisition configuration across experimental groups.
• Quantification: Define the region of interest before analysis and report the background correction, normalization method, and biological replicate structure.
• Vascular studies: Record the administration route, imaging time points, anatomical region, and criteria used to distinguish vessel-associated signal from diffuse tissue signal.
• Tumor studies: Record tumor model, tumor location, imaging time point, and tissue-processing method when fluorescence is compared with ex vivo measurements.
• Photothermal comparison: Treat 808 nm irradiation as a condition reported for the ICG-MOF-SS-AUNP12 study, not as a universal IR-820 operating parameter (Hao et al., 2023).

For users adapting the related nanoparticle literature, GSH-Responsive Indocyanine Green MOF Nanoparticles for Melanoma Therapy describes the combined delivery and immune-checkpoint concept; this article adds a compound-identity checkpoint so researchers do not mistake formulated ICG evidence for direct IR-820 evidence.

Conclusion & Outlook

IR-820, or New Indocyanine Green, is a research-stage near-infrared fluorescence dye with a product-described role in vascular and tumor imaging. Its value lies in measurable optical contrast and the resulting ability to compare tissue distribution in living-animal studies. Proper storage at 4 °C, prompt solution use, and explicit imaging controls are central to reproducible work.

The cited melanoma study demonstrates the potential of an ICG-containing nanoplatform for photothermal and immunotherapy, but it does not establish equivalent activity for free IR-820. A justified next step is direct characterization of IR-820 in the exact formulation, animal model, and optical configuration intended for the study. Such work would close the evidence gap between product-level imaging use and therapeutic nanoplatform research.